Pediatrix Medical Group (NYSE:MD) Sets New 12-Month High - Still a Buy?

Pediatrix Medical Group, Inc. (NYSE:MD - Get Free Report) shares hit a new 52-week high on Tuesday . The stock traded as high as $13.02 and last traded at $13.01, with a volume of 44878 shares trading hands. The stock had previously closed at $12.86.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Jefferies Financial Group raised shares of Pediatrix Medical Group from a "hold" rating to a "buy" rating and raised their price objective for the company from $8.00 to $14.00 in a research report on Thursday, September 26th. UBS Group raised their price objective on shares of Pediatrix Medical Group from $9.00 to $10.50 and gave the company a "neutral" rating in a research report on Friday, August 9th. Truist Financial lifted their price target on shares of Pediatrix Medical Group from $10.00 to $13.00 and gave the company a "hold" rating in a research report on Monday, October 7th. Finally, StockNews.com raised shares of Pediatrix Medical Group from a "sell" rating to a "hold" rating in a research report on Wednesday, August 7th. Five equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company's stock. According to data from MarketBeat, Pediatrix Medical Group has an average rating of "Hold" and a consensus target price of $10.90.

Pediatrix Medical Group Stock Performance

The firm's 50 day moving average price is $11.48 and its 200-day moving average price is $9.32. The firm has a market cap of $1.11 billion, a price-to-earnings ratio of -4.28, a P/E/G ratio of 1.92 and a beta of 1.56. The company has a debt-to-equity ratio of 0.87, a current ratio of 1.38 and a quick ratio of 1.38.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $0.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.31 by $0.03. The business had revenue of $504.30 million for the quarter, compared to the consensus estimate of $505.49 million. Pediatrix Medical Group had a negative net margin of 12.58% and a positive return on equity of 10.59%. Pediatrix Medical Group's quarterly revenue was up .7% on a year-over-year basis. During the same quarter last year, the company posted $0.37 earnings per share. On average, analysts anticipate that Pediatrix Medical Group, Inc. will post 1.19 earnings per share for the current year.

Insider Transactions at Pediatrix Medical Group

In other news, Director Laura A. Linynsky sold 7,000 shares of the firm's stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $11.16, for a total value of $78,120.00. Following the sale, the director now owns 30,805 shares in the company, valued at approximately $343,783.80. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, CFO C Marc Richards sold 17,438 shares of the business's stock in a transaction on Monday, August 12th. The shares were sold at an average price of $10.08, for a total value of $175,775.04. Following the sale, the chief financial officer now owns 175,347 shares in the company, valued at approximately $1,767,497.76. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Laura A. Linynsky sold 7,000 shares of the business's stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $11.16, for a total transaction of $78,120.00. Following the completion of the sale, the director now owns 30,805 shares in the company, valued at $343,783.80. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 68,100 shares of company stock worth $701,889. Insiders own 1.20% of the company's stock.

Institutional Investors Weigh In On Pediatrix Medical Group

Several institutional investors and hedge funds have recently made changes to their positions in the company. The Manufacturers Life Insurance Company raised its holdings in shares of Pediatrix Medical Group by 3.5% in the second quarter. The Manufacturers Life Insurance Company now owns 32,387 shares of the company's stock valued at $245,000 after buying an additional 1,088 shares during the last quarter. ProShare Advisors LLC raised its holdings in shares of Pediatrix Medical Group by 7.4% in the first quarter. ProShare Advisors LLC now owns 16,937 shares of the company's stock valued at $170,000 after buying an additional 1,167 shares during the last quarter. Nisa Investment Advisors LLC raised its holdings in shares of Pediatrix Medical Group by 47.2% in the second quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company's stock valued at $36,000 after buying an additional 1,524 shares during the last quarter. SummerHaven Investment Management LLC raised its holdings in shares of Pediatrix Medical Group by 3.8% in the second quarter. SummerHaven Investment Management LLC now owns 55,951 shares of the company's stock valued at $422,000 after buying an additional 2,069 shares during the last quarter. Finally, Bank of Montreal Can raised its holdings in shares of Pediatrix Medical Group by 0.5% in the second quarter. Bank of Montreal Can now owns 415,110 shares of the company's stock valued at $3,196,000 after buying an additional 2,083 shares during the last quarter. Institutional investors and hedge funds own 97.71% of the company's stock.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.